Cargando…
Deflazacort in comparison to other steroids for nephrotic syndrome
Patients with nephrotic syndrome require steroids for long time and sometimes repeatedly resulting in various adverse effects. Deflazacort (DFZ) had been described as equally effective and with fewer side effects as compared with other steroids. This review evaluates the literature on efficacy and t...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495343/ https://www.ncbi.nlm.nih.gov/pubmed/23162265 http://dx.doi.org/10.4103/0971-4065.101238 |
_version_ | 1782249487417212928 |
---|---|
author | Jat, K. R. Khairwa, A. |
author_facet | Jat, K. R. Khairwa, A. |
author_sort | Jat, K. R. |
collection | PubMed |
description | Patients with nephrotic syndrome require steroids for long time and sometimes repeatedly resulting in various adverse effects. Deflazacort (DFZ) had been described as equally effective and with fewer side effects as compared with other steroids. This review evaluates the literature on efficacy and toxicity of DFZ as compared with other therapies for nephrotic syndrome. A systematic review of Pubmed database and Cochrane Central Register of Controlled Trials with last search date of 20(th) April 2011. Search terms included “nephrotic AND deflazacort” without any limitations. Randomized control trials comparing DFZ vs placebo or other therapies in subjects with nephrotic syndrome were included. Two authors extracted data independently. Three studies meet inclusion criteria and data were synthesized qualitatively. The limited evidence suggested that DFZ appeared to be equally effective in inducing remission or decreasing proteinuria in patients with nephrotic syndrome. It caused significantly less decrease in bone mineral content (BMC) in spine as compared with prednisolone. The results related to weight change, blood pressure change, Cushingoid symptoms, and urinary calcium excretion were inconsistent between included studies. By reviewing the available limited evidence, DFZ appears to be of similar efficacy for nephrotic patients, but there were inconsistent results regarding side effect profile of DFZ as compared with other steroids except for decrease in BMC where DFZ was better. There is need for larger randomized controlled trials to evaluate effectiveness and adverse effect profile of DFZ as compared with other steroids in nephrotic syndrome. |
format | Online Article Text |
id | pubmed-3495343 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-34953432012-11-16 Deflazacort in comparison to other steroids for nephrotic syndrome Jat, K. R. Khairwa, A. Indian J Nephrol Systematic Review Patients with nephrotic syndrome require steroids for long time and sometimes repeatedly resulting in various adverse effects. Deflazacort (DFZ) had been described as equally effective and with fewer side effects as compared with other steroids. This review evaluates the literature on efficacy and toxicity of DFZ as compared with other therapies for nephrotic syndrome. A systematic review of Pubmed database and Cochrane Central Register of Controlled Trials with last search date of 20(th) April 2011. Search terms included “nephrotic AND deflazacort” without any limitations. Randomized control trials comparing DFZ vs placebo or other therapies in subjects with nephrotic syndrome were included. Two authors extracted data independently. Three studies meet inclusion criteria and data were synthesized qualitatively. The limited evidence suggested that DFZ appeared to be equally effective in inducing remission or decreasing proteinuria in patients with nephrotic syndrome. It caused significantly less decrease in bone mineral content (BMC) in spine as compared with prednisolone. The results related to weight change, blood pressure change, Cushingoid symptoms, and urinary calcium excretion were inconsistent between included studies. By reviewing the available limited evidence, DFZ appears to be of similar efficacy for nephrotic patients, but there were inconsistent results regarding side effect profile of DFZ as compared with other steroids except for decrease in BMC where DFZ was better. There is need for larger randomized controlled trials to evaluate effectiveness and adverse effect profile of DFZ as compared with other steroids in nephrotic syndrome. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3495343/ /pubmed/23162265 http://dx.doi.org/10.4103/0971-4065.101238 Text en Copyright: © Indian Journal of Nephrology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Systematic Review Jat, K. R. Khairwa, A. Deflazacort in comparison to other steroids for nephrotic syndrome |
title | Deflazacort in comparison to other steroids for nephrotic syndrome |
title_full | Deflazacort in comparison to other steroids for nephrotic syndrome |
title_fullStr | Deflazacort in comparison to other steroids for nephrotic syndrome |
title_full_unstemmed | Deflazacort in comparison to other steroids for nephrotic syndrome |
title_short | Deflazacort in comparison to other steroids for nephrotic syndrome |
title_sort | deflazacort in comparison to other steroids for nephrotic syndrome |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495343/ https://www.ncbi.nlm.nih.gov/pubmed/23162265 http://dx.doi.org/10.4103/0971-4065.101238 |
work_keys_str_mv | AT jatkr deflazacortincomparisontoothersteroidsfornephroticsyndrome AT khairwaa deflazacortincomparisontoothersteroidsfornephroticsyndrome |